Security Snapshot

Structure Therapeutics Inc. - Common Stock (GPCR) Institutional Ownership

CUSIP: 86366E106

13F Institutional Holders and Ownership History from Q1 2023 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

119

Shares (Excl. Options)

54.08MFull value: 54,076,680 · shares · 30 Sep 2026

Price

$31.27

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-1,058,750
Value change
-$76,490,324
Number of holders
119
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
215,359,875
SEC-reported price per share
$22.01
Insider filing price
$22.01
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • GPCR - Structure Therapeutics Inc. - Common Stock is tracked under CUSIP 86366E106.
  • 119 institutions reported positions in Q3 2026.
  • 7 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 191 to 119 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $3.62BFull value: $3,622,528,781 · USD · 30 Jun 2026
    to
    $1.69BFull value: $1,686,997,746 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 119 institutions filings for Q3 2026.

Open SEC evidence

Security key

86366E106

13F reference period

Q3 2026

13F holders

119

13D/G owners

7

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
7
Security
GPCR
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 15% +14% $715,915,273 +$86,831,970 32,089,434 +14% FMR LLC 30 Sep 2026
WELLINGTON MANAGEMENT GROUP LLP 14% +35% $644,649,635 +$174,385,032 29,288,943 +37% Wellington Management Group LLP 30 Sep 2026
Avoro Capital Advisors LLC 9.4% $454,066,620 16,216,665 Avoro Capital Advisors LLC 30 Sep 2025
Deep Track Capital, LP 7.2% +20% $334,650,000 +$59,448,431 15,000,000 +22% Deep Track Capital, LP 30 Sep 2026
BIOTECHNOLOGY VALUE FUND L P 4.9% -12% $723,914,898 +$57,243,848 10,437,066 +8.6% BVF PARTNERS L P/IL 31 Dec 2025
Capital Research Global Investors 3.8% $168,218,991 6,492,435 Capital Research Global Investors 31 Mar 2025
JANUS HENDERSON GROUP PLC 7.7% -3.8% $124,567,128 -$3,477,040 4,448,826 -2.7% JANUS HENDERSON GROUP PLC 30 Sep 2025
As of 30 Sep 2026, 119 institutional investors reported holding
54.08MFull value: 54,076,680 · shares · 30 Sep 2026
shares of Structure Therapeutics Inc. - Common Stock (GPCR). This represents 25% of the company’s total
215.36MFull value: 215,359,875 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
21%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
WELLINGTON MANAGEMENT GROUP LLP 4.5% 9,762,981 0.05% $305,288,416
Avoro Capital Advisors LLC 3% 6,555,555 2.1% $204,992,205
Janus Henderson Group Ltd. 2.4% 5,070,156 0.07% $158,528,870
Deep Track Capital, LP 2.3% 5,000,000 2.6% $156,350,000
BVF INC/IL 1.2% 2,691,426 2.8% $84,160,891
RTW INVESTMENTS, LP 1.1% 2,282,138 0.72% $71,362,455
BAKER BROS. ADVISORS LP 0.67% 1,432,529 0.21% $44,795,182
ORBIMED ADVISORS LLC 0.62% 1,331,000 0.76% $41,620,370
Paradigm Biocapital Advisors LP 0.6% 1,299,199 0.81% $40,625,953
DEERFIELD MANAGEMENT COMPANY, L.P. 0.5% 1,086,000 0.53% $33,959,220
Casdin Capital, LLC 0.48% 1,030,000 1.4% $32,208,100
Logos Global Management LP 0.46% 1,000,000 1.9% $31,270,000
Siren, L.L.C. 0.41% 872,967 0.65% $27,297,678
Aberdeen Group plc 0.4% 858,784 0.04% $26,854,176
CAPITOLIS LIQUID GLOBAL MARKETS LLC 0.39% 835,000 0.12% $26,110,450
Driehaus Capital Management LLC 0.37% 803,818 0.17% $25,135,389
Pacific Heights Asset Management LLC 0.37% 800,000 0.81% $25,016,000
Rock Springs Capital Management LP 0.3% 640,317 1.1% $20,022,713
ALLIANCEBERNSTEIN L.P. 0.27% 581,971 0.01% $18,198,233
Blue Sparrow, LLC /DE 0.22% 473,200 0.18% $14,796,964
TWO SIGMA INVESTMENTS, LP 0.21% 442,107 0.01% $13,824,686
GOLDMAN SACHS GROUP INC 0.2% 431,311 0% $13,487,095
NATIONAL BANK OF CANADA /FI/ 0.15% 318,545 0.01% $9,960,902
NEXTBio Capital Management LP 0.15% 312,496 4.2% $9,771,750
Parkman Healthcare Partners LLC 0.13% 283,763 0.8% $8,873,269

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
15
Headline period
Q3 2026
Rows shown
1-15 of 15
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 54,076,680 $1,686,997,746 -$76,490,324 $31.27 119
2026 Q2 67,558,328 $3,622,528,781 +$64,963,685 $53.67 191
2026 Q1 66,450,436 $3,215,748,317 -$49,596,066 $48.20 195
2025 Q4 65,776,439 $4,580,197,295 +$791,360,837 $69.55 197
2025 Q3 56,638,847 $1,582,549,935 +$86,587,271 $28.00 155
2025 Q2 54,653,188 $1,133,630,623 -$12,998,783 $20.74 172
2025 Q1 55,933,663 $980,564,651 -$97,541,400 $17.31 150
2024 Q4 60,660,143 $1,645,431,741 -$123,990,833 $27.12 162
2024 Q3 61,353,442 $2,685,754,151 +$108,882,886 $43.89 160
2024 Q2 59,255,636 $2,326,748,242 +$609,713,327 $39.27 164
2024 Q1 43,607,566 $1,861,796,908 +$49,174,094 $42.86 119
2023 Q4 42,586,066 $1,736,374,072 +$365,354,803 $40.76 121
2023 Q3 32,752,287 $1,641,782,565 +$750,250,715 $50.42 83
2023 Q2 17,647,287 $699,362,453 +$105,685,176 $41.57 48
2023 Q1 14,419,544 $343,038,725 +$343,038,726 $23.79 38
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .